New developments in Plasmodium vivax malaria: Severe disease and the rise of chloroquine resistance

Current Opinion in Infectious Diseases

Volumn 22, Issue 5, 2009, Pages 430-435

  Price, Ric N ^a,b,c   Douglas, Nicholas M ^a,c   Anstey, Nicholas M ^a,b  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b ROYAL DARWIN HOSPITAL   (Australia)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Antimalarials; Drug resistance; Malaria; Plasmodium vivax; Severe malaria

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; FANSIDAR; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE;

ANEMIA; BACTERIAL STRAIN; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; HEALTH CARE; HEALTH CARE ACCESS; HUMAN; INDIA; INDONESIA; INFECTION; NONHUMAN; PAPUA NEW GUINEA; PARASITEMIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PREVALENCE; RESPIRATORY DISTRESS; REVIEW; THAILAND; TRAVEL; TROPICS;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG RESISTANCE; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX; WORLD HEALTH;

EID: 70349158714     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32832f14c1     Document Type: Review

References (83)

1. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmo-dium vivax malaria. Am J Trop Med Hyg 2001; 64 (1-2 Suppl):97-106.
2. Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77 (6 Suppl):79-87.
3. Hay SI, Guerra CA, Tatem AJ, et al. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004; 4:327-336.
4. Baird JK. Neglect of Plasmodium vivax malaria. Trends Parasitol 2007; 23:533-539.
5. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356:297-302.
6. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev (in press).
7. Baird JK, Basri H, Purnomo, et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 1991; 44:547-552.
8. Ratcliff A, Siswantoro H, Kenangalem E, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 2007; 101:351-359.
9. Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008; 359: 2545-2557.
10. de Santana Filho FS, Arcanjo AR, Chehuan YM, et al. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis 2007; 13:1125-1126.
11. Kurcer MA, SimsekZ, ZeyrekFY, etal. Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Ann Trop Med Parasitol 2004; 98:447-451.
12. Guthmann JP, Pittet A, Lesage A, et al. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Health 2008; 13:91 -98.
13. Teka H, Petros B, Yamuah L, et al. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J 2008; 7:220.
14. Barcus MJ, Basri H, PicarimaH, etal. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 2007; 77:984-991.
15. Tjitra E, Anstey NM, Sugiarto P, etal. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5:e128.
16. Genton B, D?Acremont V, Rare L, etal. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 2008; 5:e127.
17. Kochar DK, Das A, Kochar SK, et al. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg 2009; 80:194-198.
18. Carrara VI, SirilakS, Thonglairuam J, etal. Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: The Tak Malaria initiative. PLoS Med 2006; 3:e1 83.
19. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 2009; 48:1704-1712.
20. Nosten F, McGready R, Simpson JA, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet 1999; 354:546-549.
21. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 2008; 46:1374-1381.
22. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol 2009; 25:220-227.
23. Rodriguez-Morales AJ, Sanchez E, Vargas M, et al. Is anemia in Plasmodium vivax malaria more frequent and severe than in Plasmodium falciparum? Am J Med 2006; 119:e9-e10.
24. Handayani S, Chiu DT, Tjitra E, etal. High deformability of Plasmodium vivax-infected red blood cells under microfluidic conditions. J Infect Dis 2009; 199:445-450.
25. Buffet PA, Safeukui I, Milon G, etal. Retention of erythrocytes in the spleen: a double-edged process in human malaria. Curr Opin Hematol 2009; 16:157-164.
26. Fernandez-Becerra C, Yamamoto MM, Vencio RZ, et al. Plasmodium vivax and the importance of the subtelomeric multigene vir superfamily. Trends Parasitol 2009; 25:44-51.
27. Anstey NM, Handojo T, Pain MC, et al. Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreat-ment alveolar-capillary inflammation. J Infect Dis 2007; 195:589-596.
28. Tan LK, Yacoub S, Scott S, et al. Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis 2008; 8:449-454.
29. Anstey NM, Jacups SP, Cain T, et al. Pulmonary manifestations of uncomplicated falciparum and vivax malaria: cough, small airways obstruction, impaired gas transfer, and increased pulmonary phagocytic activity. J Infect Dis 2002; 185:1326-1334.
30. Beg MA, Khan R, Baig SM, et al. Cerebral involvement in benign tertian malaria. Am J Trop Med Hyg 2002; 67:230-232.
31. Kochar DK, Saxena V, Singh N, etal. Plasmodium vivax malaria. Emerg Infect Dis 2005; 11:132-134.
32. Bejon P, Berkley JA, Mwangi T, et al. Defining childhood severe falciparum malaria for intervention studies. PLoS Med 2007; 4:e251.
33. Song HH, O SO, Kim SH, etal. Clinical features of Plasmodium vivax malaria. Korean J Intern Med 2003;18:220-224.
34. James SP. Third General Report of the Malaria Commission of the Health Organization of the League of Nations. Quart Bull Health Org of League of Nations 1933; 2:217.
35. Russell B, Chalfein F, Prasetyorini B, et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother 2008; 52:1040-1045
36. Chotivanich K, Udomsangpetch R, Simpson JA, et al. Parasite multiplication potential and the severity of Falciparum malaria. J Infect Dis 2000; 181:1206-1209.
37. Korenromp EL, Williams BG, Gouws E, et al. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 2003; 3:349-358.
38. Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003; 68:416-420.
39. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989; 2:1183-1184.
40. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 1999; 354:739-749.
41. Myint HY, Tipmanee P, Nosten F, et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 2004; 98:73-81.
42. Udomsangpetch R, Somsri S, Panichakul T, etal. Short-term in vitro culture of field isolates of Plasmodium vivax using umbilical cord blood. Parasitol Int 2007; 56:65-69.
43. Tasanor O, Ruengweerayut R, Sirichaisinthop J, et al. Clinical-parasitological response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Trans R Soc Trop Med Hyg 2006; 100:410-418.
44. Russell BM, Udomsangpetch R, Rieckmann KH, et al. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob Agents Chemother 2003; 47:170-173.
45. Chotivanich K, Udomsangpetch R, Chierakul W, et al. In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. Am J Trop Med Hyg 2004; 70:395-397.
46. Druilhe P, Brasseur P, Blanc C, Makler M. Improved assessment of Plasmo-dium vivax response to antimalarial drugs by a colorimetric double-site plasmodium lactate dehydrogenase antigen capture enzyme-linked immuno-sorbent assay. Antimicrob Agents Chemother 2007; 51:2112-2116.
47. Sharrock WW, Suwanarusk R, Lek-Uthai U, et al. Plasmodium vivax tropho-zoites insensitive to chloroquine. Malar J 2008; 7:94.
48. Suwanarusk R, Russell B, Chavchich M, et al. Chloroquine resistant Plas-modium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS ONE 2007; 2:e1089.
49. Hasugian AR, Tjitra E, Ratcliff A, et al. In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother 2009; 53:1094-1099.
50. Chotivanich K, Sattabongkot J, Choi YK, et al. Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg 2009; 80:902-904.
51. Suwanarusk R, Chavchich M, Russell B, et al. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis 2008; 198:1558-1564.
52. Lek-Uthai U, Suwanarusk R, Ruengweerayut R, et al. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob Agents Chemother 2008; 52:2435-2441.
53. Murphy GS, Basri H, Purnomo, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993; 341:96-100.
54. Sutanto I, Suprijanto S, Nurhayati, et al. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. Am J Trop Med Hyg (in press).
55. Baird JK, Sustriayu Nalim MF, Basri H, et al. Survey of resistance to chlor-oquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg 1996; 90:409-411.
56. Fryauff DJ, Tuti S, Mardi A, et al. Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia. Am J Trop Med Hyg 1998; 59:513-518.
57. Fryauff DJ, Leksana B, Masbar S, et al. The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia. Ann Trop Med Parasitol 2002; 96:447-462.
58. Phan GT, de Vries PJ, Tran BQ, et al. Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop Med Int Health 2002; 7:858-864.
59. Taylor WR, Doan HN, Nguyen DT, et al. Assessing drug sensitivity of Plasmodium vivax to halofantrine or choroquine in southern, central Vietnam using an extended 28-day in vivo test and polymerase chain reaction geno-typing. Am J Trop Med Hyg 2000; 62:693-697.
60. Lee KS, Kim TH, Kim ES, et al. Short report: chloroquine-resistant Plasmo-dium vivax in the Republic of Korea. Am J Trop Med Hyg 2009; 80:215-217.
61. Kurcer MA, Simsek Z, Kurcer Z. The decreasing efficacy of chloroquine in the treatment of Plasmodium vivax malaria, in Sanliurfa, south-eastern Turkey. Ann Trop Med Parasitol 2006; 100:109-113.
62. Barnadas C, Ratsimbasoa A, Tichit M, et al. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother 2008; 52:4233-4240.
63. Soto J, Toledo J, Gutierrez P, et al. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg 2001; 65:90-93.
64. Singh RK. Emergence of chloroquine-resistant vivax malaria in south Bihar (India). Trans R Soc Trop Med Hyg 2000; 94:327.
65. Vijaykadga S, Rojanawatsirivej C, Congpoung K, et al. Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand. Southeast Asian J Trop Med Public Health 2004; 35:566-569.
66. Valecha N, Joshi H, Eapen A, et al. Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern. Trans R Soc Trop Med Hyg 2006; 100:831-837.
67. Kolaczinski K, Durrani N, Rahim S, Rowland M. Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised noninferiority trial in eastern Afghanistan. Trans R Soc Trop Med Hyg 2007; 101:1081 -1087.
68. Leslie T, Mayan MI, Hasan MA, et al. Sulfadoxine-pyrimethamine, chlorpro-guanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA 2007; 297:2201 -2209.
69. Valibayov A, Abdullayev F, Mammadov S, et al. Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan. Acta Tropica 2003; 88:99-102.
70. Nomura T, Carlton JM, Baird JK, et al. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J Infect Dis 2001; 183:1653-1661.
71. Marfurt J, de Monbrison F, Brega S, et al. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis 2008; 198:409-417.
72. SaJM, Nomura T, Neves J, etal. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol 2005; 1 09:256-259.
73. Imwong M, Pukrittayakamee S, Pongtavornpinyo W, etal. Gene amplification of Plasmodium vivax multidrug resistance 1 gene in Thailand, Laos, and Myanmar. Antimicrob Agents Chemother 2008; 52:2657-2659.
74. Rungsihirunrat K, Sibley CH, Mungthin M, Na-Bangchang K. Geographical distribution of amino acid mutations in Plasmodium vivaxDHFR and DHPS from malaria endemic areas of Thailand. Am J Trop Med Hyg 2008; 78:462-467.
75. Zakeri S, Motmaen SR, Afsharpad M, Djadid ND. Molecular characterization of antifolates resistance-associated genes (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Malar J 2009; 8:20.
76. Tjitra E, Baker J, Suprianto S, et al. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 2002; 46:3947-3953.
77. Baird JK, Basri H, Subianto B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995; 171:1678-1682.
78. Maguire JD, Krisin, Marwoto H, et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006; 42:1067-1072.
79. Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 2002; 35:e92-e95.
80. Price RN, Hasugian AR, Ratcliff A, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 2007; 51:4090-4097.
81. Hasugian AR, Purba HL, Kenangalem E, etal. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007; 44:1067-1074.
82. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007; 369:757-765.
83. Krudsood S, Tangpukdee N, Wilairatana P, et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 2008; 78:736-740.